An AI-designed IPF drug read six years younger on six proteomic aging clocks in a 42-patient secondary analysis
Insilico Medicine / Nature Biotechnology (via r/singularity, 909 upvotes)·high signal
Insilico Medicine's rentosertib, designed by its Chemistry42 platform against TNIK, was profiled across 2,841 proteins at baseline and weeks 2, 4 and 12 in a Phase 2a idiopathic pulmonary fibrosis trial. All six independent aging clocks read treated patients as biologically younger than placebo by up to six years, with the 30mg twice-daily arm peaking around week 4 at roughly three to four years of estimated reversal. This is a secondary biomarker analysis on 42 people, not a clinical aging endpoint, and the clocks measure protein patterns rather than patient outcomes.